A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 [axitinib] At Single Doses of 5 mg, 7 mg And 10 mg, And At Multiple Doses.
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.